结合雌激素软膏在绝经后妇女阴道镜下活检的临床疗效

目的 观察结合雌激素在绝经后妇女阴道镜下活检的临床疗效。方法 分析105例绝经后妇女因细胞学异常须行阴道镜下活检的患者,分为雌激素组与对照组,对照组排除手术禁忌症行阴道镜下活检,雌激素组予结合雌激素软膏外用后行阴道镜下活检。比较两组在检查过程中的疼痛感,活检取组织时出血量,阴道镜检满意率及术后出血时间。结果 ⑴雌激素组疼痛感觉得分低于对照组,P＜0.05。⑵雌激素组阴道镜满意率80%高于对照组60%,P＜0.05。⑶雌激素组活检术中出血量和术后出血时间低于对照组,P＜0.05。结论 绝经后妇女,外用结合雌激素后阴道镜下活检,可以缓解疼痛,改善阴道镜检查的满意度,减少活检术中及术后出血,值得临床推广。     

阴道镜拟诊宫颈高级别鳞状上皮内病变与病理诊断偏差的影响因素分析

目的分析阴道镜拟诊宫颈高级别鳞状上皮内病变(high-grade squamaus intraepithelial lesion,HSIL)与病理诊断偏差的相关影响因素。方法回顾性分析2017年8月至2018年8月厦门大学附属第一医院阴道镜下拟诊为HSIL的412例患者的临床资料。对阴道镜拟诊与病理诊断的符合率进行统计,分析影响拟诊准确性的相关因素。结果 412例阴道镜拟诊为HSIL的患者中,病理证实为HSIL的288例,符合率为69.90%,其中诊断不足68例(16.51%),诊断过度56例(13.59%)。绝经前、后患者诊断符合率分别为72.58%和61.76%,差异有统计学意义(P0.05)。宫颈转化区完全可见与不完全可见患者诊断符合率分别为76.22%和64.76%,差异有统计学意义(P0.05)。先前细胞学结果在HSIL及以上与HSIL以下患者诊断符合率分别为70.88%和67.72%,差异无统计学意义(P0.05)。3个不同的阴道镜操作者诊断符合率分别为68.48%、71.13%和70.48%,差异无统计学意义(P0.05)。从诊断符合率差异有统计学意义的两组中进一步分析诊断不足的原因,发现绝经前、后诊断不足率分别为13.23%和26.47%,差异有统计学意义(P0.05),而转化区完全可见及不完全可见诊断不足率分别为15.14%及17.62%,差异无统计学意义(P0.05)。结论患者绝经状态、宫颈转化区类型均影响阴道镜拟诊HSIL的准确性,其中绝经后患者容易出现诊断不足。     

雌激素软膏在绝经后女性阴道镜下活检中的应用

目的探讨雌激素软膏在绝经后女性阴道镜下活检中的应用效果,并分析其对患者检查满意度的影响。方法选取2020年1—12月杭州市妇产科医院收治的自然绝经后女性(具有阴道镜检查指征)251例为研究对象,按随机数字表法将患者分为研究组106例和对照组145例。对照组患者行阴道镜下活检,研究组患者结合雌激素软膏进行活检。对比观察两组患者检查过程中疼痛程度(NRS)评分、术中出血量、术后出血时间、治疗过程中不良反应发生情况(皮肤水肿、局部瘙痒、便血及腹痛腹胀等)及阴道镜使用满意度。结果研究组患者术中NES评分[(3.29±1.65)分]明显低于对照组[(4.46±1.55)分],差异有统计学意义(t=3.972,P<0.05)。研究组患者术中出血量[(6.11±5.45)ml]明显低于对照组[(11.84±9.20)ml],术后出血时间[(2.82±1.43)min]明显少于对照组[(3.02±2.15)min],差异均有统计学意义(t=4.091、3.004,均P<0.05)。研究组患者皮肤水肿、局部瘙痒、便血及腹痛腹胀等不良反应发生率(2.83%、1.89%、0.94%及5.66%)均明显低于对照组(6.90%、7.59%、5.52%及11.72%),差异均有统计学意义(χ²=3.872、5.092、4.285及5.722,均P<0.05)。研究组患者阴道镜满意率(79.25%)明显高于对照组(60.00%),差异有统计学意义(χ²=5.242,P<0.05)。结论阴道镜检查前使用雌激素软膏有利于减少患者出血量,降低不良反应发生率,提高满意度和依从性,值得临床推广应用。     

倍美力软膏联合复方莪术油栓治疗绝经妇女复发性泌尿生殖道感染

目的探讨倍美力软膏联合复方莪术油栓治疗绝经妇女复发性泌尿生殖道感染的效果。方法103例绝经妇女复发性泌尿生殖道感染患者用药前后自身对照研究。结果103例患者用药后，泌尿生殖道感染症状显著改善。血清E2水平上升（p〈0．01），FSH水平显著下降（p〈0.01），子宫内膜厚度较用药前无显著变化（p〉0．05）。结论倍美力软膏联合复方莪术油栓治疗绝经妇女复发性泌尿生殖道感染，疗效明显，副反应较小，值得临床推广应用。     

保妇康栓联合雌激素软膏治疗老年阴道炎及对患者激素水平的影响观察

目的:探讨雌激素软膏联合保妇康栓治疗老年阴道炎疗效及对患者激素水平的影响。方法:选择院内收治的168例老年阴道炎患者作为研究对象,采用随机数字表法将其分为3组各56例,保妇康栓组给予保妇康栓治疗,雌激素软膏组给予单纯雌激素软膏治疗,联合治疗组给予保妇康栓联合雌激素软膏治疗;比较3组的治疗效果、激素水平变化及用药不良反应。结果:联合用药组总有效率(98.2%)高于保妇康栓组(83.9%)和雌激素软膏组(85.7%),治疗后E2、FSH、P及LH激素水平较治疗前明显改善,改善程度高于另外两组(均P0.05)。3组不良反应发生率未见差异(P0.05)。结论:保妇康栓及雌激素软膏单独应用均对老年阴道炎具有积极的治疗作用,但联合应用能获得更佳的治疗效果,调节激素水平且用药安全,值得临床应用。     

普罗雌烯治疗绝经后妇女泌尿生殖道萎缩性疾病疗效观察

目的:评价普罗雌烯阴道胶囊联合普罗雌烯软膏治疗绝经后妇女泌尿生殖道萎缩性疾病的疗效及安全性。方法:选择符合入组条件的绝经后患泌尿生殖道萎缩性疾病的妇女进行观察。普罗雌烯阴道胶囊每次1粒,每晚睡前清洁外阴后放入阴道深部;普罗雌烯软膏每晚1次适量涂抹于外阴、尿道口周围,连续20天,并对其效果进行治疗前、后的自身对比。观察泌尿生殖道萎缩相关症状的改善情况、阴道健康评分、血清E2水平及B超子宫内膜厚度的变化,综合评价疗效及安全性。结果:用药后能明显改善或基本消除泌尿生殖道萎缩的相关症状,阴道健康评分较用药前显著提高(P0.01),血清E2水平及子宫内膜厚度用药前、后均无显著性差异(P0.05)。局部用药后无明显全身副反应,无阴道流血及乳腺胀痛病例出现。结论:普罗雌烯阴道胶囊联合普罗雌烯软膏治疗绝经后妇女泌尿生殖道萎缩性疾病安全、有效。     

绝经后妇女泌尿系统感染反复发作患者小剂量雌激素预防治疗的临床疗效观察

目的探讨小剂量雌激素治疗绝经后妇女泌尿道感染的疗效。方法将2009年10月-2011年10月新乡市卫生学校附属医院收治的绝经后妇女泌尿系统感染反复发作的患者80例,随机均分为A、B两组,A组采用小剂量雌三醇（E3）软膏联合左氧氟沙星治疗,B组单用左氧氟沙星治疗。结果 A组治愈率明显高于B组（P〈0.05）,停止E3 3个月内泌尿系统感染复发率A组明显低于B组（P〈0.05）,差异有统计学意义。结论小剂量雌激素软膏阴道给药可有效治疗绝经后妇女泌尿道感染反复发作,复发率降低。     

宫颈转化区类型对阴道镜下宫颈上皮内瘤变诊断的影响

目的对阴道镜下宫颈转化区类型和宫颈上皮内瘤变(CIN)诊断进行研究,探讨宫颈转化区类型对阴道镜下宫颈CIN诊断的影响。方法 2013年1月-2015年1月台州地区宫颈癌筛查异常行阴道镜检查并活检诊断为CIN者700例作为研究对象,该700例患者均行宫颈椎切术,切除标本送病理检查。观察700例宫颈病变患者阴道镜检查情况、组织病理学检查情况,不同转化区阴道镜检查结果和病理结果符合情况,不同转化区阴道镜下活检病理和LEEP病理结果符合情况。结果 700例患者阴道镜检查结果为:Ⅰ型转化区376例,Ⅱ型转化区203例,Ⅲ型转化区121例;正常和低度病变宫颈188例,高度病变宫颈512例;组织病理学结果显示:高度病变617例,正常和低级别病变35例,宫颈癌48例。Ⅰ型转化区阴道镜检查结果和组织病理学检查结果符合率为72.6%;Ⅱ型转化区阴道镜检查结果和组织病理学检查结果符合率为71.4%;Ⅲ型转化区阴道镜检查结果和组织病理学检查结果符合率为43.8%。Ⅰ型转化区和Ⅱ型转化区阴道镜检查结果和组织病理学检查结果的符合率比较没有差异(P0.05),Ⅲ型转化区阴道镜检查结果和组织病理学检查结果的符合率低于Ⅰ型转化区和Ⅱ型转化区(P0.05)。Ⅰ型转化区、Ⅱ型转化区和Ⅲ型转化区阴道镜活检和LEEP结果的符合率分别为73.4%、67.0%和55.2%,Ⅲ型转化区阴道镜活检和LEEP结果的符合率低于Ⅰ型转化区、Ⅱ型转化区(P0.05),Ⅰ型转化区和Ⅱ型转化区阴道镜活检和LEEP结果的符合率比较,差异无统计学意义(P0.05)。Ⅰ型转化区、Ⅱ型转化区和Ⅲ型转化区高度病变阴道镜活检和LEEP结果的符合率均高于正常或低度病变的符合率(P0.05)。结论宫颈转化区类型影响阴道镜对CIN的诊断及阴道镜下活检的准确性。     

结合雌激素乳膏在绝经后萎缩性阴道炎治疗中的应用

目的 比较结合雌激素乳膏与结合雌激素软膏(倍美力软膏)治疗中国妇女绝经后萎缩性阴道炎的疗效及安全性.方法 妇科内分泌门诊募集符合入组条件的研究对象55例,分为A、B、C三组,对比用药前后受试者的阴道脱落细胞成熟指数、绝经后萎缩性阴道炎症状评分及阴道健康评分.结果 三组用药前后的阴道脱落细胞成熟指数、绝经后萎缩性阴道炎症状评分及阴道健康评分的差异有统计学意义.用药后C组血雌二醇(E2)有轻度上升,但在早卵泡期范围,血卵泡刺激素(FSH)有轻度下降趋势,但仍在绝经后水平;A、B组用药前后血E2比较差异无统计学意义.用药后A、C组子宫内膜厚度有轻度上升,差异有统计学意义.结论 阴道用结合雌激素乳膏与倍美力软膏临床疗效相似,安全性高,无严重不良反应.     

结合雌激素乳膏在绝经后萎缩性阴道炎治疗中的应用

目的比较结合雌激素乳膏与结合雌激素软膏（倍美力软膏）治疗中国妇女绝经后萎缩性阴道炎的疗效及安全性。方法妇科内分泌门诊募集符合入组条件的研究对象55例，分为A、B、C三组，对比用药前后受试者的阴道脱落细胞成熟指数、绝经后萎缩性阴道炎症状评分及阴道健康评分。结果三组用药前后的阴道脱落细胞成熟指数、绝经后萎缩性阴道炎症状评分及阴道健康评分的差异有统计学意义。用药后C组血雌二醇（E：）有轻度上升，但在早卵泡期范围，血卵泡刺激素（码H）有轻度下降趋势，但仍在绝经后水平；A、B组用药前后血E2比较差异无统计学意义。用药后A、C组子宫内膜厚度有轻度上升，差异有统计学意义。结论阴道用结合雌激素乳膏与倍美力软膏临床疗效相似，安全性高，无严重不良反应。     

Effect of local conjugated estrogens on vaginal pH in elderly women

OBJECTIVE: The decline in estrogens during and after menopause is associated with an increase in vaginal pH and an increased susceptibility to urinary tract infections (UTIs). Decreased vaginal pH following short-term treatment with topical estrogens may reduce the incidence of such infections. This study was undertaken to evaluate the effect of low-dose, topical conjugated estrogens vaginal cream (CEVC) on vaginal pH in older, postmenopausal women. DESIGN: We conducted a retrospective analysis of initial and follow-up evaluations of older, postmenopausal women residing in 19 long-term care facilities who were referred to Seton Health System's Incontinence Treatment Center between January 2, 1997, and June 13, 1998. Patients were untreated or were administered conjugated estrogens intravaginally (0.5 g/d, 3 days per week). SETTING: Incontinence Treatment Center, Seton Health System. PARTICIPANTS: Two hundred fifty-eight postmenopausal women (mean age 83 years), residents of skilled nursing facilities, who were diagnosed with urinary incontinence, were included in the study. MEASUREMENTS: Measurements included age, CEVC treatment, vaginal pH, and history of UTIs or hysterectomy. RESULTS: In the CEVC-treated women, vaginal pH was reduced from a mean of 7.41 +/- 0.71 to 6.80 +/- 0.70 after 6 weeks (n = 213; P = 0.0001). No differences in vaginal pH were observed in untreated women (n = 45). Continuation of CEVC treatment for an additional 6 weeks (n = 93) resulted in further decreases in vaginal pH (P = 0.017). Women who discontinued treatment after 6 weeks maintained a lower vaginal pH for 6 weeks (P = 0.0004), and there was no significant difference between groups at Week 12. CONCLUSIONS: Low-dose CEVC for 6 and 12 weeks reduces vaginal pH in older women residing in long-term care facilities. The decreased vaginal pH following short-term treatment with topical estrogens may reduce the incidence of recurrent UTIs.     

Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

Elevated plasma homocysteine levels have been associated with increased atherosclerotic disease risk. Estrogen and estrogen/progestin replacement therapy have been suggested to lower plasma homocysteine levels in postmenopausal women. To assess the impact of hormone replacement therapy (HRT) on plasma homocysteine, levels were measured in samples from adherent women randomized to placebo (n = 34), conjugated equine estrogens (n = 36), or continuous conjugated equine estrogens + progestin (n = 33) in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Homocysteine levels decreased between baseline and follow-up (12 and 36 months) in all treatment groups. The magnitude of the reduction was greater in the conjugated estrogens group at 12 months compared with placebo (p = 0.036), even when adjusted for folate and B vitamin consumption, but this difference did not persist at 36 months. These data suggest that estrogen therapy has a modest, but transient, impact on plasma homocysteine levels in women with normal homocysteine at baseline.     

Estrogen use in postmenopausal women.

Fifteen per cent of postmenopausal women living in a retirement community used oral estrogens. Both use and new-use continued in the seventh, eighth and ninth decades of life, although use and age-specific use-prevalence declined after age 70. Mean duration of most recent continuous use was 105 months. Vaginal estrogenic preparations were used infrequently, briefly, and usually by women who also used oral estrogens in the same year. The most commonly used oral estrogenic preparation was conjugated equine estrogens (Premarin).     

倍美力软膏配伍金霉素软膏在绝经后妇女子宫脱垂术前的临床应用

目的: 探讨倍美力软膏配伍金霉素软膏在绝经后妇女子宫脱垂行阴式子宫切除+阴道前后壁修补术前的临床应用效果。方法: 对 36例绝经后Ⅱ度、Ⅲ度子宫脱垂患者术前给予倍美力软膏配伍金霉素软膏阴道内上药 (研究组 ), 每日 1次,共 3~5d, 与 30例未用药者 (对照组) 比较, 观察两组术中出血量及手术时间和术后病率。结果: 研究组术中出血量及手术时间和术后病率明显少于对照组 (P<0. 01)。结论: 绝经后妇女子宫脱垂阴式子宫切除 +阴道前后壁修补术前给予倍美力软膏配伍金霉素软膏阴道用药, 可减少术中出血, 缩短手术时间, 减少术后病率, 促进术后愈合, 可作为术前常规用药。     

武汉市妇女绝经相关因素的调查

目的评估武汉市40~65岁妇女自然绝经过程中绝经相关症状的发生及影响因素。方法选取2014年4~10月武汉市参加年度健康体检、年龄40~65岁的956名妇女为调查对象,采用问卷形式调查妇女的基本信息、月经状况、运动锻炼情况、重要躯体疾病以及围绝经期相关症状,用Greene评分法评估绝经症状,分析绝经症状的发生情况及影响因素。结果月经不规律妇女出现的得分高的前五位绝经相关症状是:感到疲惫或精力不足、失眠、感到头晕或无力、潮热、肌肉或关节酸痛(P0.05);得分高的常见的症候群是:焦虑症状、躯体症状、抑郁症状和血管舒缩症状(P0.05)。绝经后妇女出现的得分高的绝经症状是:失眠、潮热、感到疲倦或精力不足和肌肉关节酸痛(P0.05);常见症候群是血管舒缩症状和性生活问题(P0.05)。躯体疾病对5种绝经症候群均有显著影响(P0.05);40~50岁者较61~65岁者更易有抑郁症状(P0.05);体质量指数增加更易有血管舒缩症状(P0.05)。结论绝经症状在绝经的各个阶段侧重表现不同,慢性躯体疾病是绝经症状的不良影响因素。     

The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms

Abstract Background: Menopause-related health issues, including vasomotor symptoms, vulvar/vaginal atrophy, and osteoporosis, can decrease women's quality of life. Hormone therapy is the primary treatment option targeting both menopausal symptoms and bone loss but has been associated with some safety concerns. The tissue selective estrogen complex (TSEC) is a novel therapy, partnering a selective estrogen receptor modulator (SERM) with one or more estrogens. The pairing of bazedoxifene (BZA) with conjugated estrogens (CE) has been evaluated in the Selective estrogens, Menopause, And Response to Therapy (SMART) phase 3 trials. This article reviews key findings for BZA/CE and discusses its potential as a treatment option for postmenopausal women. Methods: A review of BZA/CE findings from the SMART trials was conducted based on relevant publications and presentations. Results: BZA 20?mg/CE 0.45 and 0.625?mg have been shown to reduce hot flush frequency (by 74% and 80%, respectively, versus 51% for placebo [SMART-2 trial]) and severity, improve measures of vulvar/vaginal atrophy (SMART-3 trial), and prevent bone loss (mean percent change in lumbar spine bone mineral density [BMD] of 0.24 and 0.60, respectively, versus-1.28 for placebo [SMART-5 trial]) in postmenopausal women. These BZA/CE doses are associated with a favorable safety and tolerability profile, with high rates of cumulative amenorrhea and low incidences of breast pain. Overall, BZA/CE has been shown to be effective in relieving menopausal symptoms and preventing osteoporosis while maintaining endometrial and breast safety. Conclusions: BZA/CE is a unique TSEC and a promising option for postmenopausal women seeking a safe and comprehensive therapy.     

人工流产术前应用奥湿克最佳时间的探讨

目的　探讨人工流产术前应用奥湿克的最佳时间。　方法　采用前瞻性的随机对照研究方法 ,共有妇女 466人入选 ,随机分为 5组。对照组 ,负压吸宫前不加用任何药物 ;用药组分 0 .5、1、 2及 3 h共 4组 ,每组均空腹 1次口服奥湿克 2片 ,分别在服药后 0 .5、 1、 2、 3 h行负压吸宫术。　结果　在消除了混杂因素的影响后 ,3 h组宫颈扩张程度最大 (P<0 .0 0 5) ;0 .5、 1、 2、 3 h组 4组手术时间均比对照组明显缩短 (P<0 .0 0 5) ;0 .5、 1、 2 h组术中出血量均比对照组及 3 h组明显减少 (P<0 .0 0 5) ;0 .5h组术中疼痛程度最轻 (P<0 .0 5)。　结论　术前应用奥湿克应根据不同的目的选择用药时间。人工流产术前 3 0 min口服奥湿克对于缓解术中疼痛、减少术中出血量及缩短手术时间的效果最好 ,人工流产术前 3 h口服奥湿克则对于扩张宫颈的作用最大     

高危型人乳头瘤病毒E6/E7 mRNA检测在意义不明的非典型鳞状上皮细胞中的分流价值

目的研究高危型人乳头瘤病毒(high-risk human papillomavirus,hrH PV)E 6/E 7 mRNA在结果意义不明的非典型鳞状上皮细胞(atypical squamous cells of undetermined significance,ASCUS)中的分流效率,探索其在ASCUS分流中的临床价值。方法选取2013年至2015年在青岛市立医院妇科门诊行细胞学筛查结果为ASCUS的女性405例,年龄21~65岁。根据HPV检测方法,分为3组:HC2组、HPV分型组、hrH PV E 6/E 7 mRNA(E6/E7)组。比较3种HPV检测方法分流ASCUS的灵敏度、特异度、阳性预测值、阴性预测值、阴道镜转诊率、CIN 2~+/CIN 3~+检出率。结果 (1)E 6/E 7分流ASCUS的CIN 2~+灵敏度为100.00%(90.51%~100.00%),CIN 2~+/CIN 3~+的特异度分别为64.84%(53.06%~75.99%)、56.46%(43.98%~69.72%),阴性预测值分别为100.00%(99.41%~100.00%)、100.00%(99.34%~100.00%),与HC2和HPV分型比较差异无统计学意义(P>0.05)。阳性预测值分别为40.79%(37.91%~44.29%)、15.79%(10.07%~20.94%),高于HC2(P<0.05)。阴道镜转诊率为47.80%,低于HC2和HPV分型(P<0.05)。CIN 2~+检出率为19.50%,高于HC2(P<0.05)。(2)E 6/E 7分流ASCUS检测CIN 2~+的曲线下面积为0.815,>HC2和HPV分型(P<0.05)。结论 hrH PV E 6/E 7mRNA分流ASCUS的灵敏度、特异度与HC2相似,PPV和CIN 2~+检出率更高,阴道镜转诊率更低,可用于ASCUS的分流。     

Noncontraceptive estrogen use and epithelial ovarian cancer

The relation of noncontraceptive estrogen use to epithelial ovarian cancer was evaluated in a case-control study conducted in hospitals mainly in the northeastern United States. There were 377 cases diagnosed within the year before hospital admission and 2,030 hospital controls; data were collected by interview in the hospital. Compared with women who never took noncontraceptive estrogens, the overall relative risk estimate for women whose estrogen use lasted at least one year and was not combined with progestogens or testosterone was 1.2 (95% confidence interval (CI) 0.8-1.9), after taking into account risk factors for ovarian cancer. There were 55 cases of the endometrioid, clear cell, or malignant mixed mesodermal cell type; the corresponding relative risk estimate was 0.9 (95% CI 0.3-3.0). There were 26 cases of undifferentiated cell type, with a relative risk estimate of 3.6 (95% CI 1.2-11). Relative risk estimates were similar in a subset of the cases (57%) for which pathology slides were reviewed. For estrogen use of long duration, use of high-dose preparations, or use in the distant past, the relative risk estimates were not significantly different from 1.0. The estimates were elevated for some categories of use, but not consistently--for example, for an interval of 5-9 years since estrogen use began (relative risk (RR) = 2.7), but not after shorter or longer intervals, and for use of conjugated estrogens with a dose of 0.3 mg (RR = 3.2) or 1.25 mg (RR = 2.4), but not for doses of 0.625 mg or 2.5 mg. The relative risk estimate was also elevated for use by nulliparous women (RR = 2.4). The results suggest that, overall, noncontraceptive estrogen use is not associated with the risk of epithelial ovarian cancer. Furthermore, our data do not support the hypothesis that estrogens increase the risk of endometrioid ovarian cancer. The elevated estimates could be due to multiple stratification of the data, but they should be explored in further studies, given the lethality of ovarian cancer and the common use of estrogens by postmenopausal women.     

绝经后取环术采取宫术宁胶棒对提高患者取环成功率和取环疼痛情况的临床观察

目的 探究女性绝经后取环术采取宫术宁胶棒辅助取环的临床效果,并为患者临床取环积累经验. 方法 选取本站所计划生育科2008年4月-2010年3月收治的70例绝经后接受经宫颈取环的女性,采取常规取环操作,设为对照组;选取2011年4月-2013年3月收治的72例绝经后接受经宫颈取环的妇女,采取宫术宁胶棒辅助取环,设为研究组.记录两组患者取环成功率及取环疼痛情况,并做好对比. 结果 研究组宫颈扩张情况及取环成功率均优于对照组,且差异有统计学意义（P＜0.05）;研究组取环疼痛程度低于对照组,且差异有统计学意义（P＜0.05）. 结论 绝经后女性采取宫术宁胶棒辅助取环可提高取环成功率,并降低患者疼痛感,临床效果较佳,值得进一步推广.